Immune cell therapy for sepsis with low white blood cell counts
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests NAI, an experimental immune cell therapy, for patients hospitalized with sepsis (a life-threatening infection response) who have persistently low white blood cell counts. The treatment aims to restore immune function and help the body fight the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are in the ICU with sepsis diagnosed by specific organ failure criteria
- You have had persistently low white blood cell counts (below 1,000) confirmed twice within 72 hours
- You have already started appropriate antibiotics or other infection-fighting medications
- You can provide written consent or have a legal representative who can
- If able to have children, you agree to use effective birth control for up to 7 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (NAI) added to standard care for sepsis in the ICU to see if it helps improve immune function and recovery. It is for people with very low lymphocyte counts who meet specific timing and health requirements.
This Phase 2 trial tests an immune-boosting cell therapy (umbilical mesenchymal stromal cells) in people with septic shock—when infection causes dangerous stress on the heart and other organs. The goal is to see if this treatment can improve outcomes compared with standard care.
This trial tests a medical device (NucleoCapture) that may remove substances called circulating DNA and NETs from the blood in people with sepsis and breathing failure. The goal is to check safety and see whether it can improve blood markers and possibly outcomes.
This trial tests a personalized approach to giving IV fluids to patients with sepsis in the emergency department. It uses a device to monitor your heart and blood flow to help doctors decide how much fluid you need, which may improve recovery.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial tests a new blood-cleansing device (HemoSystem REBOOT) that may help people with sepsis by removing harmful substances and improving immune function. It is for critically ill patients whose immune systems remain suppressed despite standard sepsis treatment.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.